UPTRAVI reduced PAH progression by 40%1

UPTRAVI can reduce the risk of PAH progression by up to 40%

UPTRAVI® (selexipag) helps you stay ahead of your disease by reducing PAH-related hospitalizations and other PAH disease progression events.

  • 27.0% of patients treated with UPTRAVI experienced a PAH disease progression event vs 41.6% of patients on placebo (a sugar pill)
Uptravi can be used as a PAH monotherapy or PAH combination therapy

In a clinical study of UPTRAVI, PAH disease progression was defined as a serious event, such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy; lung transplantation; a decline in 6-minute walk distance (6MWD) combined with worsening of functional class (FC) or need for additional PAH therapy; or death.